Patents by Inventor Marie-Louise Fjaellskog

Marie-Louise Fjaellskog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY MOLECULES TO CD73 AND USES THEREOF
    Publication number: 20230039109
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: March 15, 2022
    Publication date: February 9, 2023
    Inventors: Bianka Prinz, Jerry M. Thomas, Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Scott Chappel, Andrew Lake, Alison Paterson, Rachel W. O'Connor, Michael Warren, Pamela Holland, Kulandayan Kasi Subramanian, Helena Marie-Louise Fjaellskog, Dirksen Bussiere, Mikias Woldegiorgis, Wei Shu, John Delmas Venable, III, Michael Gladstone, Jonathan Hill, Christine Miller
  • ANTIBODY MOLECULES TO CD73 AND USES THEREOF
    Publication number: 20210214459
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 15, 2021
    Inventors: Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Kulandayan Kasi Subramanian, Marie-Louise Fjaellskog, John Delmas Venable, III, Bianka Prinz, Jerry M. Thomas, Andrew Lake, Scott Chappel, Pamela Holland, Michael Warren, Alison Paterson, Rachel W. O'Connor, Michael Gladstone, Jonathan Hill, Christine Miller
  • Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
    Patent number: 11001628
    Abstract: The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: May 11, 2021
    Assignee: NOVARTIS AG
    Inventors: Marie-Louise Fjaellskog, John Scott Cameron, Zhu Cao, Daniela Cipolletta, Kenzie MacIsaac
  • ANTIBODY MOLECULES TO CD73 AND USES THEREOF
    Publication number: 20190031766
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: June 21, 2018
    Publication date: January 31, 2019
    Inventors: Bianka Prinz, Jerry M. Thomas, Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Scott Chapel, Andrew Lake, Alison Paterson, Rachel W. O'Connor, Michael Warren, Pamela Holland, Kulandayan Kasi Subramanian, Marie-Louise Fjaellskog, Dirksen Bussiere, Mikias Woldegiorgis, Wei Shu, John Delmas Venable III
  • COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER
    Publication number: 20180222973
    Abstract: The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 9, 2018
    Inventors: Marie-Louise Fjaellskog, John Scott Cameron, Zhu Cao, Daniela Cipolletta, kenzie Maclsaac